Drugs / ECCEC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06726174 | Apr 2025 → Dec 2028 expected | corneal disorder | National Taiwan University Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ECCEC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06726174 ↗ |
| Action | Restore | “Eventually, they will reconstitute functional corneal endothelium” NCT06726174 ↗ |
| Modality | Cell therapy | “After ex vivo cultivation, the cells will be injected into anterior chamber” NCT06726174 ↗ |
| Route | Other | “intracameral injection.” NCT06726174 ↗ |